The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation

Molecular Cell

Volumn 5, Issue 6, 2000, Pages 939-948

  Lonard, David M ^a   Nawaz, Zafar ^a   Smith, Carolyn L ^a   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; PROTEASOME; UBIQUITIN;

ANIMAL CELL; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; GENETIC TRANSFECTION; HORMONE PROTEIN COMPLEX; HORMONE RECEPTOR INTERACTION; HORMONE TRANSPORT; HUMAN; HUMAN CELL; LIGAND BINDING; MOUSE; NONHUMAN; POINT MUTATION; PROTEIN DOMAIN; RECEPTOR DOWN REGULATION; TRANSACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

ANIMALIA;

EID: 0033638393     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1097-2765(00)80259-2     Document Type: Article

References (67)

1. Proteasome-mediated proteolysis of estrogen receptor: A novel component in autologous downregulation
2. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation
3. The proteasome: Paradigm of a self-compartmentalizing protease
4. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain
5. Molecular basis of agonism and antagonism in the oestrogen receptor
6. Degradation of nuclear oncoproteins by the ubiquitin system in vitro
7. Structure and functions of the 20S and 26S proteasomes
8. Identification of a conserved region required for hormone dependent transcriptional activation by steroid hormone receptors
9. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique
10. WAF1, a potential mediator of p53 tumor suppression
11. Implication of proteasome in estrogen receptor degradation
12. Protein synthesis is not implicated in the ligand-dependent activation of the estrogen receptor in MCF-7 cells
13. Thermolability of ubiquitin-activating enzyme from the mammalian cell cycle mutant ts85
14. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor
15. Nuclear receptor coactivators
16. Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor
17. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A
18. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
19. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors
20. Estradiol-stimulated proteolytic cleavage of the estrogen receptor in mouse uterus
21. Actinomycin D prevents nuclear processing of estrogen receptor
22. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18
23. Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors
24. Estrogen-binding substances of target tissues
25. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway
26. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells
27. Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells
28. Nuclear protein CBP is a coactivator for the transcription factor CREB
29. Cloning of a novel receptor expressed in rat prostate and ovary
30. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
31. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome
32. Phosphorylation of the human estrogen receptor
33. Interaction of thyroid-hormone receptor with a conserved transcriptional mediator
34. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2
35. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin
36. Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins
37. Molecular determinants of the estrogen receptor-coactivator interface
38. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line
39. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
40. Nuclear receptor coactivators: Multiple enzymes, multiple complexes, multiple functions
41. Characterization of the subunit nature of nuclear estrogen receptors by chemical cross-linking and dense amino acid labeling
42. Characterization of the estrogen receptor and its dynamics in MCF-7 human breast cancer cells using a covalently attaching antiestrogen
43. The nuclear receptor ligand-binding domain: Structure and function
44. ER β: Identification and characterization of a novel human estrogen receptor
45. Dynamics of estrogen receptor turnover in uterine cells in vitro and in uteri in vivo
46. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily
47. Proteasome-dependent degradation of the human estrogen receptor
48. Ubiquitination of the rat uterine estrogen receptor: Dependence on estradiol
49. 9-cis-retinoic acid decreases the level of its cognate receptor, retinoid X receptor, through acceleration of the turnover
50. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
51. An assessment of the role of domain F and PEST sequences in estrogen receptor half-life and bioactivity
52. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B
53. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription
54. Regulation of estrogen receptor messenger ribonucleic acid and protein levels in human breast cancer cell lines by sex steroid hormones, their antagonists, and growth factors
55. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules
56. Regulation of the estrogen receptor in MCF-7 cells by estradiol
57. The estrogen receptor in MCF-7 cells: Evidence from dense amino acid labeling for rapid turnover and a dimeric model of activated nuclear receptor
58. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
59. Evidence for enhanced ubiquitin-mediated proteolysis of the chicken progesterone receptor by progesterone
60. Competition between thyroid hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor (TIF) 2 for binding to nuclear receptors. Implications for the recruitment of TRAP and p160 coactivator complexes
61. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
62. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
63. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors
64. Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1
65. Tamoxifen activation of the estrogen receptor/AP1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
66. Estrogen receptor activation function 1 works by binding p160 coactivator proteins
67. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells